Please login to the form below

Not currently logged in
Email:
Password:

cell cancer

This page shows the latest cell cancer news and features for those working in and with pharma, biotech and healthcare.

Nektar confirms BMS deal for NKTR-214 is on track

Nektar confirms BMS deal for NKTR-214 is on track

studies of NKTR-214 in front-line and second-/third-line non–small-cell lung cancer (NSCLC) in the second-quarter, and are now working on 20 indications across nine tumour ... Robin said that studies are now underway or planned for the CD122-biased

Latest news

  • Lilly adds to pharma M&A run with $8bn Loxo buy-out Lilly adds to pharma M&A run with $8bn Loxo buy-out

    exactly which patients may benefit, creates new opportunities to improve the lives of people with advanced cancer.". ... Loxo. LOXO-292 is seen as the firm’s prize asset, as it has potential in the non-small cell lung cancer field.

  • Orphan drugs dominate FDA's record-breaking year Orphan drugs dominate FDA's record-breaking year

    Gottlieb also promises to speed biosimilars and cell and gene therapies in 2019. ... The last few days of the year also saw approvals for Stemline Therapeutics’ Elzonris (tagraxofusp) – the first drug to be licensed for rare cancer blastic

  • Horizon Discovery and C4X to harness CRISPR for new cancer drugs Horizon Discovery and C4X to harness CRISPR for new cancer drugs

    Horizon has used its target discovery platform to conduct CRISPR gene knock-out studies across multiple cancer cell lines, screening around 3000 genes suitable as the basis for small molecule drug ... These work by targeting a specific DNA repair pathway

  • AZ still sees route to approval for Imfinzi in MYSTIC trial AZ still sees route to approval for Imfinzi in MYSTIC trial

    New analysis shows opportunity in NSCLC. AstraZeneca isn’t giving up on its aspirations for Imfinzi in first-line non-small cell lung cancer (NSCLC), and against all odds thinks the ... A high TMB reading indicates more markers on the cancer cell

  • BMS to test Vedanta’s bacterial therapy with Opdivo BMS to test Vedanta’s bacterial therapy with Opdivo

    In animal studies presented at this year’s Society for Immunotherapy of Cancer (SITC) meeting, VE800 on its own and alongside PD-1 inhibitors showed anti-tumour effects, including cytotoxic T ... cell infiltration into the cancer, suppression of tumour

More from news
Approximately 1 fully matching, plus 653 partially matching documents found.

Latest Intelligence

  • Is China ready for a pharmaceutical gold rush?

    Bristol-Myers Squibb’s (BMS)’s Opdivo (nivolumab) was approved for the treatment of non-small cell lung cancer (NSCLC) in June. ... The programmed cell death 1 (PD-1) immune checkpoint inhibitor works by restoring the immune system’s ability to

  • Combined immunotherapies – potential and pitfalls Combined immunotherapies – potential and pitfalls

    Cancers by their very nature are unique. The huge range of potential causes of the abnormal cell division that characterises cancer mean that every tumour is different. ... Drug development is outpacing our capacity to develop biomarkers due to the

  • China: AstraZeneca’s new engine for growth and innovation China: AstraZeneca’s new engine for growth and innovation

    Other key launches will include Lynparza, its ovarian cancer treatment, now co-marketed globally with MSD. ... Its Imfinzi has secured the first-ever US and EU approval in locally- advanced, unresectable non-small cell lung cancer – a potentially

  • Chinese biotech’s global ambitions Chinese biotech’s global ambitions

    has just achieved a landmark approval in China for its own ‘home-grown’ cancer medicine. ... Tislelizumab is in global phase III trials in a number of tumour types, including non-small cell lung cancer, hepatocellular carcinoma and oesophageal

  • Cancer immunotherapy: What's on the horizon? Cancer immunotherapy: What's on the horizon?

    had transformative results in some diseases such as melanoma, non-small cell lung cancer and bladder cancer – among others. ... Non-small cell lung cancer (NSCLC) is a prime example of the impact the new PD-(L) 1 drugs can have.

More from intelligence
Approximately 0 fully matching, plus 35 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 6 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 8 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Videum Health

Videum Health is a premium video platform that offers brands innovative engagement strategies to reach targeted healthcare audiences on a...

Latest intelligence

The new UK government-pharma industry pricing agreement – welcome news, but there are lessons to be learnt
...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again – in exchange for uptake promises...
Digital applications are transforming the market access landscape
Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....

Infographics